201 related articles for article (PubMed ID: 18534874)
1. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
4. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
5. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
Levitt JM; Jian W; Lerner SP; Sonpavde G
Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
[TBL] [Abstract][Full Text] [Related]
8. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.
Chan ES; Patel AR; Hansel DE; Larchian WA; Heston WD
Urology; 2012 Sep; 80(3):736.e1-5. PubMed ID: 22676953
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer.
Yoon YK; Im SA; Min A; Kim HP; Hur HS; Lee KH; Han SW; Song SH; Youn Oh D; Kim TY; Kim WH; Bang YJ
Cancer Lett; 2012 Aug; 321(2):128-36. PubMed ID: 22266184
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
Suddek GM
Cancer Chemother Pharmacol; 2011 May; 67(5):1035-44. PubMed ID: 20652569
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
[TBL] [Abstract][Full Text] [Related]
16. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
Gao H; Jiang Q; Han Y; Peng J; Wang C
Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model.
Mousseau Y; Mollard S; Faucher-Durand K; Richard L; Nizou A; Cook-Moreau J; Baaj Y; Qiu H; Plainard X; Fourcade L; Funalot B; Sturtz FG
Breast Cancer Res Treat; 2012 Jul; 134(1):31-40. PubMed ID: 22160641
[TBL] [Abstract][Full Text] [Related]
18. Emetine dihydrochloride: a novel therapy for bladder cancer.
Foreman KE; Jesse JN; Kuo PC; Gupta GN
J Urol; 2014 Feb; 191(2):502-9. PubMed ID: 24045224
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
20. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]